Vectura Group PLC (LON:VEC) insider Bruno Angelici purchased 70,000 shares of the company’s stock in a transaction on Tuesday, September 12th. The stock was acquired at an average cost of GBX 99 ($1.28) per share, for a total transaction of £69,300 ($89,500.19).

Shares of Vectura Group PLC (VEC) opened at 103.50 on Friday. The stock’s 50 day moving average price is GBX 108.65 and its 200-day moving average price is GBX 126.28. The company’s market capitalization is GBX 702.25 million. Vectura Group PLC has a 52-week low of GBX 88.90 and a 52-week high of GBX 166.97.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/09/14/bruno-angelici-buys-70000-shares-of-vectura-group-plc-vec-stock.html.

Several research analysts have commented on the company. Numis Securities Ltd reaffirmed a “buy” rating and issued a GBX 205 ($2.65) price target on shares of Vectura Group PLC in a research report on Thursday, September 7th. Peel Hunt reaffirmed a “hold” rating and issued a GBX 160 ($2.07) price target on shares of Vectura Group PLC in a research report on Wednesday, September 6th. Panmure Gordon reaffirmed a “buy” rating on shares of Vectura Group PLC in a research report on Wednesday, August 30th. Shore Capital reaffirmed a “buy” rating on shares of Vectura Group PLC in a research report on Wednesday, August 16th. Finally, N+1 Singer reaffirmed a “hold” rating on shares of Vectura Group PLC in a research report on Thursday, June 29th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of GBX 209 ($2.70).

Vectura Group PLC Company Profile

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Insider Buying and Selling by Quarter for Vectura Group PLC (LON:VEC)

Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.